跳至主要内容
临床试验/ACTRN12618000208202
ACTRN12618000208202已完成1 期

A single dose, randomized, open label, pilot study of a test formulation of atorvastatin oral spray in a 2 way crossover comparison against the innovator atorvastatin capsule conducted under fasting conditions in healthy male and female volunteers

Zenith Technology Corp Ltd0 个研究点目标入组 12 人开始时间: 2018年2月9日最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
入组人数
12

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 55 Years(—)
性别
All

入选标准

  • Healthy male and non-pregnant females
  • Aged between 18 and 55
  • Non-smoker
  • BMI between 18.5 and 30 inclusive
  • Normal, healthy individuals as determined by medical history, physical examination, ECG, blood pressure and laboratory tests
  • Able to provide written informed consent

排除标准

  • Any history of recent recurrent attacks of bronchitis, asthma, migraine headaches
  • Concomitant drug therapy of any kind
  • Sensitivity to the study drug
  • History of any conditions that might interfere with the absorption, distribution, metabolism or excretion of the drug
  • Females who are pregnant and/or are breastfeeding
  • Smoker (anyone who has smoked in the last 6 months)
  • History of alcohol or drug abuse or dependency
  • Participation in a drug study within 60 days of the start of the study or donated blood in the 60 days preceding the study.
  • Volunteers for whom the Clinical Investigator believes, for any reason, that participation would not be an acceptable risk

研究者

相似试验

已完成
1 期
A randomised, open label study to compare the bioavailability of 12mg (2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoic acid capsules against the innovator 10mg (2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoic acid capsules conducted under fasting condition in healthy male volunteers.Tretinoin capsules are indicated for the induction of remission in patients with acute promyelocytic leukemia (APL), French-American-British (FAB) classification M3 (including the M3 variant), characterized by the presence of the t(1517) translocation and/or the presence of the PML/RARa gene who are refractory to, or who have relapsed from, anthracycline chemotherapy, or for whom anthracycline-based chemotherapy is contraindicated. Tretinoin is for the induction of remission only.Cancer - Leukaemia - Chronic leukaemia
ACTRN12620000287932Zenith Technology Corporation Limited24
招募中
不适用
A randomized, open-label, and single-dose study to evaluate the safety and the pharmacokinetics after concurrent administration of UIC202007 and UIC202008 in healthy adult subjects
KCT0005901Korea United Pharm30
已完成
1 期
Comparative assessment of the absorption of 3 generic formulations of isotretinoin capsules against the innovator isotretinoin capsule in a pilot study conducted under fasting conditions in healthy male volunteers
ACTRN12615000569505Zenith Technology Corp Ltd16
已完成
1 期
Mass balance study of [14C]-REN001 in healthy male subjectsPrimary mitochondrial myopathy (rare genetic diseases that cause muscles to not function properly)Genetic Diseases
ISRCTN57533271Reneo Pharma Ltd6
尚未招募
1 期
A Single Dose, Randomized, Open-label, One-period Parallel Bioequivalence Study of Generic Leflunomide 20 mg Film-coated Tablets and Reference Product (Arava) in Healthy Thai Male Volunteers under Fasting ConditionsBioequivalence Study Healthy Thai VolunteersLeflunomide 20 mg Film-coated Tablets Bioequivalence Study Healthy Thai Volunteers
TCTR20210215001International Bio Service Co.,Ltd.44